CHARACTERIZATION OF BACTEREMIC AND NON-BACTEREMIC SYNDROMES OF INVASIVE ESCHERICHIA COLI DISEASE AMONG HOSPITALIZED ADULTS AGED ≥60 YEARS: FINDINGS FROM A PROSPECTIVE, MULTINATIONAL, OBSERVATIONAL STUDY (EXPECT-2) Article Swipe
Joachim Doua
,
Jesús Rodríguez‐Baño
,
Christine Vallejo
,
P. Puranam
,
Oscar Go
,
Jeroen Geurtsen
,
Sanne van Rooij
,
Tuba Vilken
,
Inage Minoru
,
I. Yasumori
,
Bart Spiessens
,
Evelina Tacconelli
,
Lena M. Biehl
,
Joshua T. Thaden
,
Michal Sarnecki
,
Herman Goossens
,
Jan Poolman
,
Marc J. M. Bonten
,
Miquel B. Ekkelenkamp
·
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.1016/j.ijid.2023.04.271
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.1016/j.ijid.2023.04.271
Intro: Published data is limited in describing clinical features and disease burden of invasive Escherichia coli disease (IED). This study characterized bacteremic and non-bacteremic IED in relation to clinical features and multidrug resistance (MDR) of causative E. coli isolates. Methods: EXPECT-2 (NCT04117113) was a multinational, hospital-based, observational study that prospectively enrolled IED patients aged ≥60 years between October 2019 and January 2021. IED was defined by a positive E. coli culture from blood (bacteremic IED), a sterile body site or urine (non-bacteremic IED) in the presence of requisite criteria of Systemic Inflammatory Response Syndrome (SIRS), Sequential Organ Failure Assessment (SOFA), or quick SOFA (qSOFA). In-hospital mortality and IED-related medical encounters were assessed through 28 days following IED diagnosis. MDR was defined as acquired non-susceptibility to ≥1 antibiotic in ≥3 antimicrobial classes. Findings: The full analysis set included 193 bacteremic (80.4%) and 47 non- bacteremic (19.6%) patients. Patient demographics were balanced between bacteremic and non-bacteremic IED. The rates of patients with ≥2 SIRS criteria were comparable between bacteremic (64.8%) and non-bacteremic IED (70.2%). The rates of patients with the ≥2-point change in total SOFA score were comparable between bacteremic (62.2%) and non-bacteremic IED (53.2%). The rates of sepsis and septic shock were 75.0% and 11.4%, respectively, for bacteremic, and 83.3% and 7.1%, respectively, for non-bacteremic IED. The most common IED-related medical encounter was the emergency room both in patients with bacteremic (31.5%, [41/130]) and non-bacteremic IED (35.9%, [14/39]). Of 11 patients who died, 6 (54.5%) had bacteremic IED. Of 294 E. coli isolates with antimicrobial susceptibility testing collected from 238 patients, MDR rates were 34.7% (87/251) for bacteremic and 37.2% (16/43) for non-bacteremic isolates. Conclusion: IED manifested as severe infection, with approximately one-third of E. coli isolates displaying MDR. Bacteremic and non-bacteremic IED were characterized by similar clinical features and MDR phenotypes.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1016/j.ijid.2023.04.271
- https://doi.org/10.1016/j.ijid.2023.04.271
- OA Status
- gold
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4377042281
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4377042281Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1016/j.ijid.2023.04.271Digital Object Identifier
- Title
-
CHARACTERIZATION OF BACTEREMIC AND NON-BACTEREMIC SYNDROMES OF INVASIVE ESCHERICHIA COLI DISEASE AMONG HOSPITALIZED ADULTS AGED ≥60 YEARS: FINDINGS FROM A PROSPECTIVE, MULTINATIONAL, OBSERVATIONAL STUDY (EXPECT-2)Work title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2023Year of publication
- Publication date
-
2023-05-01Full publication date if available
- Authors
-
Joachim Doua, Jesús Rodríguez‐Baño, Christine Vallejo, P. Puranam, Oscar Go, Jeroen Geurtsen, Sanne van Rooij, Tuba Vilken, Inage Minoru, I. Yasumori, Bart Spiessens, Evelina Tacconelli, Lena M. Biehl, Joshua T. Thaden, Michal Sarnecki, Herman Goossens, Jan Poolman, Marc J. M. Bonten, Miquel B. EkkelenkampList of authors in order
- Landing page
-
https://doi.org/10.1016/j.ijid.2023.04.271Publisher landing page
- PDF URL
-
https://doi.org/10.1016/j.ijid.2023.04.271Direct link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.1016/j.ijid.2023.04.271Direct OA link when available
- Concepts
-
Observational study, Medicine, Disease, Bacteremia, Prospective cohort study, Internal medicine, Microbiology, Biology, AntibioticsTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4377042281 |
|---|---|
| doi | https://doi.org/10.1016/j.ijid.2023.04.271 |
| ids.doi | https://doi.org/10.1016/j.ijid.2023.04.271 |
| ids.openalex | https://openalex.org/W4377042281 |
| fwci | 0.0 |
| type | article |
| title | CHARACTERIZATION OF BACTEREMIC AND NON-BACTEREMIC SYNDROMES OF INVASIVE ESCHERICHIA COLI DISEASE AMONG HOSPITALIZED ADULTS AGED ≥60 YEARS: FINDINGS FROM A PROSPECTIVE, MULTINATIONAL, OBSERVATIONAL STUDY (EXPECT-2) |
| biblio.issue | |
| biblio.volume | 130 |
| biblio.last_page | S110 |
| biblio.first_page | S109 |
| topics[0].id | https://openalex.org/T13569 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9927999973297119 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2713 |
| topics[0].subfield.display_name | Epidemiology |
| topics[0].display_name | Microscopic Colitis |
| topics[1].id | https://openalex.org/T11153 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9904000163078308 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2739 |
| topics[1].subfield.display_name | Public Health, Environmental and Occupational Health |
| topics[1].display_name | Streptococcal Infections and Treatments |
| topics[2].id | https://openalex.org/T11551 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9898999929428101 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2713 |
| topics[2].subfield.display_name | Epidemiology |
| topics[2].display_name | Infective Endocarditis Diagnosis and Management |
| is_xpac | False |
| apc_list.value | 1750 |
| apc_list.currency | USD |
| apc_list.value_usd | 1750 |
| apc_paid.value | 1750 |
| apc_paid.currency | USD |
| apc_paid.value_usd | 1750 |
| concepts[0].id | https://openalex.org/C23131810 |
| concepts[0].level | 2 |
| concepts[0].score | 0.6892529129981995 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q818574 |
| concepts[0].display_name | Observational study |
| concepts[1].id | https://openalex.org/C71924100 |
| concepts[1].level | 0 |
| concepts[1].score | 0.5994635820388794 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[1].display_name | Medicine |
| concepts[2].id | https://openalex.org/C2779134260 |
| concepts[2].level | 2 |
| concepts[2].score | 0.5204413533210754 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q12136 |
| concepts[2].display_name | Disease |
| concepts[3].id | https://openalex.org/C2779443120 |
| concepts[3].level | 3 |
| concepts[3].score | 0.503023087978363 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q650912 |
| concepts[3].display_name | Bacteremia |
| concepts[4].id | https://openalex.org/C188816634 |
| concepts[4].level | 2 |
| concepts[4].score | 0.4611828923225403 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q2113324 |
| concepts[4].display_name | Prospective cohort study |
| concepts[5].id | https://openalex.org/C126322002 |
| concepts[5].level | 1 |
| concepts[5].score | 0.30476924777030945 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[5].display_name | Internal medicine |
| concepts[6].id | https://openalex.org/C89423630 |
| concepts[6].level | 1 |
| concepts[6].score | 0.27115747332572937 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q7193 |
| concepts[6].display_name | Microbiology |
| concepts[7].id | https://openalex.org/C86803240 |
| concepts[7].level | 0 |
| concepts[7].score | 0.15789514780044556 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q420 |
| concepts[7].display_name | Biology |
| concepts[8].id | https://openalex.org/C501593827 |
| concepts[8].level | 2 |
| concepts[8].score | 0.04078403115272522 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q12187 |
| concepts[8].display_name | Antibiotics |
| keywords[0].id | https://openalex.org/keywords/observational-study |
| keywords[0].score | 0.6892529129981995 |
| keywords[0].display_name | Observational study |
| keywords[1].id | https://openalex.org/keywords/medicine |
| keywords[1].score | 0.5994635820388794 |
| keywords[1].display_name | Medicine |
| keywords[2].id | https://openalex.org/keywords/disease |
| keywords[2].score | 0.5204413533210754 |
| keywords[2].display_name | Disease |
| keywords[3].id | https://openalex.org/keywords/bacteremia |
| keywords[3].score | 0.503023087978363 |
| keywords[3].display_name | Bacteremia |
| keywords[4].id | https://openalex.org/keywords/prospective-cohort-study |
| keywords[4].score | 0.4611828923225403 |
| keywords[4].display_name | Prospective cohort study |
| keywords[5].id | https://openalex.org/keywords/internal-medicine |
| keywords[5].score | 0.30476924777030945 |
| keywords[5].display_name | Internal medicine |
| keywords[6].id | https://openalex.org/keywords/microbiology |
| keywords[6].score | 0.27115747332572937 |
| keywords[6].display_name | Microbiology |
| keywords[7].id | https://openalex.org/keywords/biology |
| keywords[7].score | 0.15789514780044556 |
| keywords[7].display_name | Biology |
| keywords[8].id | https://openalex.org/keywords/antibiotics |
| keywords[8].score | 0.04078403115272522 |
| keywords[8].display_name | Antibiotics |
| language | en |
| locations[0].id | doi:10.1016/j.ijid.2023.04.271 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S35071406 |
| locations[0].source.issn | 1201-9712, 1878-3511 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 1201-9712 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | International Journal of Infectious Diseases |
| locations[0].source.host_organization | https://openalex.org/P4310320990 |
| locations[0].source.host_organization_name | Elsevier BV |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320990 |
| locations[0].source.host_organization_lineage_names | Elsevier BV |
| locations[0].license | |
| locations[0].pdf_url | https://doi.org/10.1016/j.ijid.2023.04.271 |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | International Journal of Infectious Diseases |
| locations[0].landing_page_url | https://doi.org/10.1016/j.ijid.2023.04.271 |
| locations[1].id | pmh:oai:doaj.org/article:f0440870f8b947879f63398dba451189 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306401280 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | DOAJ (DOAJ: Directory of Open Access Journals) |
| locations[1].source.host_organization | |
| locations[1].source.host_organization_name | |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | submittedVersion |
| locations[1].raw_type | article |
| locations[1].license_id | |
| locations[1].is_accepted | False |
| locations[1].is_published | False |
| locations[1].raw_source_name | International Journal of Infectious Diseases, Vol 130, Iss , Pp S109-S110 (2023) |
| locations[1].landing_page_url | https://doaj.org/article/f0440870f8b947879f63398dba451189 |
| indexed_in | crossref, doaj |
| authorships[0].author.id | https://openalex.org/A5087885675 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-3503-3596 |
| authorships[0].author.display_name | Joachim Doua |
| authorships[0].countries | BE, GB |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I47508984 |
| authorships[0].affiliations[0].raw_affiliation_string | Imperial College London, Infectious Disease, London, United Kingdom |
| authorships[0].affiliations[1].institution_ids | https://openalex.org/I137982388 |
| authorships[0].affiliations[1].raw_affiliation_string | Janssen Research & Development, Janssen Pharmaceutica, Infectious Diseases & Vaccines, Beerse, Belgium |
| authorships[0].institutions[0].id | https://openalex.org/I137982388 |
| authorships[0].institutions[0].ror | https://ror.org/04yzcpd71 |
| authorships[0].institutions[0].type | company |
| authorships[0].institutions[0].lineage | https://openalex.org/I1330063522, https://openalex.org/I137982388 |
| authorships[0].institutions[0].country_code | BE |
| authorships[0].institutions[0].display_name | Janssen (Belgium) |
| authorships[0].institutions[1].id | https://openalex.org/I47508984 |
| authorships[0].institutions[1].ror | https://ror.org/041kmwe10 |
| authorships[0].institutions[1].type | education |
| authorships[0].institutions[1].lineage | https://openalex.org/I47508984 |
| authorships[0].institutions[1].country_code | GB |
| authorships[0].institutions[1].display_name | Imperial College London |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | J. Doua |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Imperial College London, Infectious Disease, London, United Kingdom, Janssen Research & Development, Janssen Pharmaceutica, Infectious Diseases & Vaccines, Beerse, Belgium |
| authorships[1].author.id | https://openalex.org/A5063919113 |
| authorships[1].author.orcid | https://orcid.org/0000-0001-6732-9001 |
| authorships[1].author.display_name | Jesús Rodríguez‐Baño |
| authorships[1].countries | ES, GB |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I4210133602 |
| authorships[1].affiliations[0].raw_affiliation_string | University of Sevilla and Biomedicine Institute of Sevilla/CSIC, Department of Medicine, Seville, Spain |
| authorships[1].affiliations[1].institution_ids | https://openalex.org/I47508984 |
| authorships[1].affiliations[1].raw_affiliation_string | Imperial College London, Bioengineering, London, United Kingdom |
| authorships[1].affiliations[2].institution_ids | https://openalex.org/I4210090436 |
| authorships[1].affiliations[2].raw_affiliation_string | Hospital Universitario Virgen Macarena, Unidad Clínica de Enfermedades Infecciosas y Microbiología, Sevilla, Spain |
| authorships[1].affiliations[3].institution_ids | https://openalex.org/I2801357902 |
| authorships[1].affiliations[3].raw_affiliation_string | Instituto de Salud Carlos III, CIBERINFEC, Madrid, Spain |
| authorships[1].institutions[0].id | https://openalex.org/I4210090436 |
| authorships[1].institutions[0].ror | https://ror.org/016p83279 |
| authorships[1].institutions[0].type | healthcare |
| authorships[1].institutions[0].lineage | https://openalex.org/I4210090436 |
| authorships[1].institutions[0].country_code | ES |
| authorships[1].institutions[0].display_name | Hospital Universitario Virgen Macarena |
| authorships[1].institutions[1].id | https://openalex.org/I4210133602 |
| authorships[1].institutions[1].ror | https://ror.org/031zwx660 |
| authorships[1].institutions[1].type | facility |
| authorships[1].institutions[1].lineage | https://openalex.org/I134820265, https://openalex.org/I158283456, https://openalex.org/I4210133602, https://openalex.org/I79238269, https://openalex.org/I918821925 |
| authorships[1].institutions[1].country_code | ES |
| authorships[1].institutions[1].display_name | Instituto de Biomedicina de Sevilla |
| authorships[1].institutions[2].id | https://openalex.org/I2801357902 |
| authorships[1].institutions[2].ror | https://ror.org/00ca2c886 |
| authorships[1].institutions[2].type | nonprofit |
| authorships[1].institutions[2].lineage | https://openalex.org/I2801357902, https://openalex.org/I4387152914 |
| authorships[1].institutions[2].country_code | ES |
| authorships[1].institutions[2].display_name | Instituto de Salud Carlos III |
| authorships[1].institutions[3].id | https://openalex.org/I47508984 |
| authorships[1].institutions[3].ror | https://ror.org/041kmwe10 |
| authorships[1].institutions[3].type | education |
| authorships[1].institutions[3].lineage | https://openalex.org/I47508984 |
| authorships[1].institutions[3].country_code | GB |
| authorships[1].institutions[3].display_name | Imperial College London |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | J. Rodríguez-Baño |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Hospital Universitario Virgen Macarena, Unidad Clínica de Enfermedades Infecciosas y Microbiología, Sevilla, Spain, Imperial College London, Bioengineering, London, United Kingdom, Instituto de Salud Carlos III, CIBERINFEC, Madrid, Spain, University of Sevilla and Biomedicine Institute of Sevilla/CSIC, Department of Medicine, Seville, Spain |
| authorships[2].author.id | https://openalex.org/A5049631502 |
| authorships[2].author.orcid | |
| authorships[2].author.display_name | Christine Vallejo |
| authorships[2].countries | FR |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I4210159361, https://openalex.org/I154526488 |
| authorships[2].affiliations[0].raw_affiliation_string | Dupuytren University Hospital, Emergency Department and Inserm Clinical Investigation Center, Limoges, France |
| authorships[2].institutions[0].id | https://openalex.org/I4210159361 |
| authorships[2].institutions[0].ror | https://ror.org/053385a79 |
| authorships[2].institutions[0].type | healthcare |
| authorships[2].institutions[0].lineage | https://openalex.org/I4210097159, https://openalex.org/I4210130325, https://openalex.org/I4210159361 |
| authorships[2].institutions[0].country_code | FR |
| authorships[2].institutions[0].display_name | Hôpital Dupuytren |
| authorships[2].institutions[1].id | https://openalex.org/I154526488 |
| authorships[2].institutions[1].ror | https://ror.org/02vjkv261 |
| authorships[2].institutions[1].type | government |
| authorships[2].institutions[1].lineage | https://openalex.org/I154526488 |
| authorships[2].institutions[1].country_code | FR |
| authorships[2].institutions[1].display_name | Inserm |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | C. Vallejo |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Dupuytren University Hospital, Emergency Department and Inserm Clinical Investigation Center, Limoges, France |
| authorships[3].author.id | https://openalex.org/A5091975031 |
| authorships[3].author.orcid | |
| authorships[3].author.display_name | P. Puranam |
| authorships[3].countries | CA |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I2802851750 |
| authorships[3].affiliations[0].raw_affiliation_string | Health Sciences North Research Institute, Infectious Prevention and Control, Sudbury, Canada |
| authorships[3].institutions[0].id | https://openalex.org/I2802851750 |
| authorships[3].institutions[0].ror | https://ror.org/04br0rs05 |
| authorships[3].institutions[0].type | healthcare |
| authorships[3].institutions[0].lineage | https://openalex.org/I2802851750 |
| authorships[3].institutions[0].country_code | CA |
| authorships[3].institutions[0].display_name | Health Sciences North |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | P. Puranam |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Health Sciences North Research Institute, Infectious Prevention and Control, Sudbury, Canada |
| authorships[4].author.id | https://openalex.org/A5113635658 |
| authorships[4].author.orcid | |
| authorships[4].author.display_name | Oscar Go |
| authorships[4].countries | US |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I4210151386 |
| authorships[4].affiliations[0].raw_affiliation_string | Janssen Research & Development, US Stats & Dec Scien, Raritan, NJ, United States of America |
| authorships[4].institutions[0].id | https://openalex.org/I4210151386 |
| authorships[4].institutions[0].ror | https://ror.org/05af73403 |
| authorships[4].institutions[0].type | company |
| authorships[4].institutions[0].lineage | https://openalex.org/I1330063522, https://openalex.org/I4210151386 |
| authorships[4].institutions[0].country_code | US |
| authorships[4].institutions[0].display_name | Janssen (United States) |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | O. Go |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Janssen Research & Development, US Stats & Dec Scien, Raritan, NJ, United States of America |
| authorships[5].author.id | https://openalex.org/A5053179149 |
| authorships[5].author.orcid | https://orcid.org/0000-0002-8234-846X |
| authorships[5].author.display_name | Jeroen Geurtsen |
| authorships[5].countries | NL |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I4210102948, https://openalex.org/I4210154236 |
| authorships[5].affiliations[0].raw_affiliation_string | Janssen Vaccines & Prevention B.V., Leiden, Bacterial Vaccines Discovery and Early Development, Leiden, Netherlands |
| authorships[5].institutions[0].id | https://openalex.org/I4210102948 |
| authorships[5].institutions[0].ror | https://ror.org/018ypnc38 |
| authorships[5].institutions[0].type | nonprofit |
| authorships[5].institutions[0].lineage | https://openalex.org/I4210102948, https://openalex.org/I4210131117 |
| authorships[5].institutions[0].country_code | NL |
| authorships[5].institutions[0].display_name | Human Vaccines Project Europe |
| authorships[5].institutions[1].id | https://openalex.org/I4210154236 |
| authorships[5].institutions[1].ror | https://ror.org/04cxegr21 |
| authorships[5].institutions[1].type | company |
| authorships[5].institutions[1].lineage | https://openalex.org/I1330063522, https://openalex.org/I4210154236 |
| authorships[5].institutions[1].country_code | NL |
| authorships[5].institutions[1].display_name | Janssen (Netherlands) |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | J. Geurtsen |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Janssen Vaccines & Prevention B.V., Leiden, Bacterial Vaccines Discovery and Early Development, Leiden, Netherlands |
| authorships[6].author.id | https://openalex.org/A5054672858 |
| authorships[6].author.orcid | |
| authorships[6].author.display_name | Sanne van Rooij |
| authorships[6].countries | NL |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I3018483916 |
| authorships[6].affiliations[0].raw_affiliation_string | University Medical Center Utrecht, Julius Center for Health Sciences and Primary Care, Utrecht, Netherlands |
| authorships[6].institutions[0].id | https://openalex.org/I3018483916 |
| authorships[6].institutions[0].ror | https://ror.org/0575yy874 |
| authorships[6].institutions[0].type | healthcare |
| authorships[6].institutions[0].lineage | https://openalex.org/I3018483916 |
| authorships[6].institutions[0].country_code | NL |
| authorships[6].institutions[0].display_name | University Medical Center Utrecht |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | S. van Rooij |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | University Medical Center Utrecht, Julius Center for Health Sciences and Primary Care, Utrecht, Netherlands |
| authorships[7].author.id | https://openalex.org/A5058733181 |
| authorships[7].author.orcid | https://orcid.org/0009-0005-1769-1682 |
| authorships[7].author.display_name | Tuba Vilken |
| authorships[7].countries | BE |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I149213910 |
| authorships[7].affiliations[0].raw_affiliation_string | Vaccine & Infectious Disease Institute, University of Antwerp, Laboratory of Medical Microbiology, Antwerp, Belgium |
| authorships[7].institutions[0].id | https://openalex.org/I149213910 |
| authorships[7].institutions[0].ror | https://ror.org/008x57b05 |
| authorships[7].institutions[0].type | education |
| authorships[7].institutions[0].lineage | https://openalex.org/I149213910 |
| authorships[7].institutions[0].country_code | BE |
| authorships[7].institutions[0].display_name | University of Antwerp |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | T. Vilken |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Vaccine & Infectious Disease Institute, University of Antwerp, Laboratory of Medical Microbiology, Antwerp, Belgium |
| authorships[8].author.id | https://openalex.org/A5091975032 |
| authorships[8].author.orcid | |
| authorships[8].author.display_name | Inage Minoru |
| authorships[8].affiliations[0].raw_affiliation_string | Okitama Public General Hospital, Respiratory Medicine, Kawanishi, Japan |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | I. Minoru |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | Okitama Public General Hospital, Respiratory Medicine, Kawanishi, Japan |
| authorships[9].author.id | https://openalex.org/A5091975030 |
| authorships[9].author.orcid | |
| authorships[9].author.display_name | I. Yasumori |
| authorships[9].countries | JP |
| authorships[9].affiliations[0].institution_ids | https://openalex.org/I4210118695 |
| authorships[9].affiliations[0].raw_affiliation_string | National Hospital Organization Nagasaki Medical Center, Department of General Internal Medicine, Nagasaki, Japan |
| authorships[9].institutions[0].id | https://openalex.org/I4210118695 |
| authorships[9].institutions[0].ror | https://ror.org/02qv90y91 |
| authorships[9].institutions[0].type | healthcare |
| authorships[9].institutions[0].lineage | https://openalex.org/I4210118695, https://openalex.org/I4210137409 |
| authorships[9].institutions[0].country_code | JP |
| authorships[9].institutions[0].display_name | Nagasaki Medical Center |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | I. Yasumori |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | National Hospital Organization Nagasaki Medical Center, Department of General Internal Medicine, Nagasaki, Japan |
| authorships[10].author.id | https://openalex.org/A5106765143 |
| authorships[10].author.orcid | |
| authorships[10].author.display_name | Bart Spiessens |
| authorships[10].countries | BE, GB |
| authorships[10].affiliations[0].institution_ids | https://openalex.org/I47508984 |
| authorships[10].affiliations[0].raw_affiliation_string | Imperial College London, Infectious Disease, London, United Kingdom |
| authorships[10].affiliations[1].institution_ids | https://openalex.org/I137982388 |
| authorships[10].affiliations[1].raw_affiliation_string | Janssen Research & Development, Janssen Pharmaceutica, Infectious Diseases & Vaccines, Beerse, Belgium |
| authorships[10].institutions[0].id | https://openalex.org/I137982388 |
| authorships[10].institutions[0].ror | https://ror.org/04yzcpd71 |
| authorships[10].institutions[0].type | company |
| authorships[10].institutions[0].lineage | https://openalex.org/I1330063522, https://openalex.org/I137982388 |
| authorships[10].institutions[0].country_code | BE |
| authorships[10].institutions[0].display_name | Janssen (Belgium) |
| authorships[10].institutions[1].id | https://openalex.org/I47508984 |
| authorships[10].institutions[1].ror | https://ror.org/041kmwe10 |
| authorships[10].institutions[1].type | education |
| authorships[10].institutions[1].lineage | https://openalex.org/I47508984 |
| authorships[10].institutions[1].country_code | GB |
| authorships[10].institutions[1].display_name | Imperial College London |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | B. Spiessens |
| authorships[10].is_corresponding | False |
| authorships[10].raw_affiliation_strings | Imperial College London, Infectious Disease, London, United Kingdom, Janssen Research & Development, Janssen Pharmaceutica, Infectious Diseases & Vaccines, Beerse, Belgium |
| authorships[11].author.id | https://openalex.org/A5110693550 |
| authorships[11].author.orcid | |
| authorships[11].author.display_name | Evelina Tacconelli |
| authorships[11].countries | IT |
| authorships[11].affiliations[0].institution_ids | https://openalex.org/I119439378 |
| authorships[11].affiliations[0].raw_affiliation_string | Department of Diagnostic and Public Health, Verona, Italy |
| authorships[11].affiliations[1].institution_ids | https://openalex.org/I119439378 |
| authorships[11].affiliations[1].raw_affiliation_string | University of Verona, Division of Infectious Diseases, |
| authorships[11].institutions[0].id | https://openalex.org/I119439378 |
| authorships[11].institutions[0].ror | https://ror.org/039bp8j42 |
| authorships[11].institutions[0].type | education |
| authorships[11].institutions[0].lineage | https://openalex.org/I119439378 |
| authorships[11].institutions[0].country_code | IT |
| authorships[11].institutions[0].display_name | University of Verona |
| authorships[11].author_position | middle |
| authorships[11].raw_author_name | E. Tacconelli |
| authorships[11].is_corresponding | False |
| authorships[11].raw_affiliation_strings | Department of Diagnostic and Public Health, Verona, Italy, University of Verona, Division of Infectious Diseases, |
| authorships[12].author.id | https://openalex.org/A5031922965 |
| authorships[12].author.orcid | https://orcid.org/0000-0001-7613-8119 |
| authorships[12].author.display_name | Lena M. Biehl |
| authorships[12].countries | DE |
| authorships[12].affiliations[0].institution_ids | https://openalex.org/I4210153755 |
| authorships[12].affiliations[0].raw_affiliation_string | University Hospital of Cologne, Department of Internal Medicine, Cologne, Germany |
| authorships[12].affiliations[1].institution_ids | https://openalex.org/I4210115305 |
| authorships[12].affiliations[1].raw_affiliation_string | Partner site Bonn-Cologne, German Centre for Infection Research, Bonn-Cologne, Germany |
| authorships[12].institutions[0].id | https://openalex.org/I4210115305 |
| authorships[12].institutions[0].ror | https://ror.org/028s4q594 |
| authorships[12].institutions[0].type | facility |
| authorships[12].institutions[0].lineage | https://openalex.org/I4210115305, https://openalex.org/I4411590659 |
| authorships[12].institutions[0].country_code | DE |
| authorships[12].institutions[0].display_name | German Center for Infection Research |
| authorships[12].institutions[1].id | https://openalex.org/I4210153755 |
| authorships[12].institutions[1].ror | https://ror.org/05mxhda18 |
| authorships[12].institutions[1].type | healthcare |
| authorships[12].institutions[1].lineage | https://openalex.org/I4210153755 |
| authorships[12].institutions[1].country_code | DE |
| authorships[12].institutions[1].display_name | University Hospital Cologne |
| authorships[12].author_position | middle |
| authorships[12].raw_author_name | L. Biehl |
| authorships[12].is_corresponding | False |
| authorships[12].raw_affiliation_strings | Partner site Bonn-Cologne, German Centre for Infection Research, Bonn-Cologne, Germany, University Hospital of Cologne, Department of Internal Medicine, Cologne, Germany |
| authorships[13].author.id | https://openalex.org/A5085866405 |
| authorships[13].author.orcid | https://orcid.org/0000-0002-3250-0697 |
| authorships[13].author.display_name | Joshua T. Thaden |
| authorships[13].countries | US |
| authorships[13].affiliations[0].institution_ids | https://openalex.org/I170897317 |
| authorships[13].affiliations[0].raw_affiliation_string | Duke University School of Medicine, Department of Medicine, Division of Infectious Diseases, Durham, United States of America |
| authorships[13].institutions[0].id | https://openalex.org/I170897317 |
| authorships[13].institutions[0].ror | https://ror.org/00py81415 |
| authorships[13].institutions[0].type | education |
| authorships[13].institutions[0].lineage | https://openalex.org/I170897317 |
| authorships[13].institutions[0].country_code | US |
| authorships[13].institutions[0].display_name | Duke University |
| authorships[13].author_position | middle |
| authorships[13].raw_author_name | J. Thaden |
| authorships[13].is_corresponding | False |
| authorships[13].raw_affiliation_strings | Duke University School of Medicine, Department of Medicine, Division of Infectious Diseases, Durham, United States of America |
| authorships[14].author.id | https://openalex.org/A5032467622 |
| authorships[14].author.orcid | https://orcid.org/0000-0001-7035-0020 |
| authorships[14].author.display_name | Michal Sarnecki |
| authorships[14].countries | CH |
| authorships[14].affiliations[0].institution_ids | https://openalex.org/I4210113301 |
| authorships[14].affiliations[0].raw_affiliation_string | Janssen Vaccines, Cilag GmbH International, Bern, Switzerland |
| authorships[14].institutions[0].id | https://openalex.org/I4210113301 |
| authorships[14].institutions[0].ror | https://ror.org/01y2qtb13 |
| authorships[14].institutions[0].type | company |
| authorships[14].institutions[0].lineage | https://openalex.org/I1330063522, https://openalex.org/I4210113301 |
| authorships[14].institutions[0].country_code | CH |
| authorships[14].institutions[0].display_name | Janssen (Switzerland) |
| authorships[14].author_position | middle |
| authorships[14].raw_author_name | M. Sarnecki |
| authorships[14].is_corresponding | False |
| authorships[14].raw_affiliation_strings | Janssen Vaccines, Cilag GmbH International, Bern, Switzerland |
| authorships[15].author.id | https://openalex.org/A5010374583 |
| authorships[15].author.orcid | https://orcid.org/0000-0003-4891-4031 |
| authorships[15].author.display_name | Herman Goossens |
| authorships[15].countries | BE |
| authorships[15].affiliations[0].institution_ids | https://openalex.org/I149213910 |
| authorships[15].affiliations[0].raw_affiliation_string | Vaccine & Infectious Disease Institute, University of Antwerp, Laboratory of Medical Microbiology, Antwerp, Belgium |
| authorships[15].institutions[0].id | https://openalex.org/I149213910 |
| authorships[15].institutions[0].ror | https://ror.org/008x57b05 |
| authorships[15].institutions[0].type | education |
| authorships[15].institutions[0].lineage | https://openalex.org/I149213910 |
| authorships[15].institutions[0].country_code | BE |
| authorships[15].institutions[0].display_name | University of Antwerp |
| authorships[15].author_position | middle |
| authorships[15].raw_author_name | H. Goossens |
| authorships[15].is_corresponding | False |
| authorships[15].raw_affiliation_strings | Vaccine & Infectious Disease Institute, University of Antwerp, Laboratory of Medical Microbiology, Antwerp, Belgium |
| authorships[16].author.id | https://openalex.org/A5038094499 |
| authorships[16].author.orcid | https://orcid.org/0000-0002-9583-8126 |
| authorships[16].author.display_name | Jan Poolman |
| authorships[16].countries | NL |
| authorships[16].affiliations[0].institution_ids | https://openalex.org/I4210102948, https://openalex.org/I4210154236 |
| authorships[16].affiliations[0].raw_affiliation_string | Janssen Vaccines & Prevention B.V., Leiden, Bacterial Vaccines Discovery and Early Development, Leiden, Netherlands |
| authorships[16].institutions[0].id | https://openalex.org/I4210102948 |
| authorships[16].institutions[0].ror | https://ror.org/018ypnc38 |
| authorships[16].institutions[0].type | nonprofit |
| authorships[16].institutions[0].lineage | https://openalex.org/I4210102948, https://openalex.org/I4210131117 |
| authorships[16].institutions[0].country_code | NL |
| authorships[16].institutions[0].display_name | Human Vaccines Project Europe |
| authorships[16].institutions[1].id | https://openalex.org/I4210154236 |
| authorships[16].institutions[1].ror | https://ror.org/04cxegr21 |
| authorships[16].institutions[1].type | company |
| authorships[16].institutions[1].lineage | https://openalex.org/I1330063522, https://openalex.org/I4210154236 |
| authorships[16].institutions[1].country_code | NL |
| authorships[16].institutions[1].display_name | Janssen (Netherlands) |
| authorships[16].author_position | middle |
| authorships[16].raw_author_name | J. Poolman |
| authorships[16].is_corresponding | False |
| authorships[16].raw_affiliation_strings | Janssen Vaccines & Prevention B.V., Leiden, Bacterial Vaccines Discovery and Early Development, Leiden, Netherlands |
| authorships[17].author.id | https://openalex.org/A5055970684 |
| authorships[17].author.orcid | https://orcid.org/0000-0002-9095-9201 |
| authorships[17].author.display_name | Marc J. M. Bonten |
| authorships[17].countries | NL |
| authorships[17].affiliations[0].institution_ids | https://openalex.org/I3018483916 |
| authorships[17].affiliations[0].raw_affiliation_string | University Medical Center Utrecht, Julius Center for Health Sciences and Primary Care, Utrecht, Netherlands |
| authorships[17].institutions[0].id | https://openalex.org/I3018483916 |
| authorships[17].institutions[0].ror | https://ror.org/0575yy874 |
| authorships[17].institutions[0].type | healthcare |
| authorships[17].institutions[0].lineage | https://openalex.org/I3018483916 |
| authorships[17].institutions[0].country_code | NL |
| authorships[17].institutions[0].display_name | University Medical Center Utrecht |
| authorships[17].author_position | middle |
| authorships[17].raw_author_name | M. Bonten |
| authorships[17].is_corresponding | False |
| authorships[17].raw_affiliation_strings | University Medical Center Utrecht, Julius Center for Health Sciences and Primary Care, Utrecht, Netherlands |
| authorships[18].author.id | https://openalex.org/A5002135002 |
| authorships[18].author.orcid | https://orcid.org/0000-0001-5475-7875 |
| authorships[18].author.display_name | Miquel B. Ekkelenkamp |
| authorships[18].countries | NL |
| authorships[18].affiliations[0].institution_ids | https://openalex.org/I3018483916 |
| authorships[18].affiliations[0].raw_affiliation_string | University Medical Center Utrecht, Department of Medical Microbiology, Utrecht, Netherlands |
| authorships[18].institutions[0].id | https://openalex.org/I3018483916 |
| authorships[18].institutions[0].ror | https://ror.org/0575yy874 |
| authorships[18].institutions[0].type | healthcare |
| authorships[18].institutions[0].lineage | https://openalex.org/I3018483916 |
| authorships[18].institutions[0].country_code | NL |
| authorships[18].institutions[0].display_name | University Medical Center Utrecht |
| authorships[18].author_position | last |
| authorships[18].raw_author_name | M. Ekkelenkamp |
| authorships[18].is_corresponding | False |
| authorships[18].raw_affiliation_strings | University Medical Center Utrecht, Department of Medical Microbiology, Utrecht, Netherlands |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.1016/j.ijid.2023.04.271 |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | CHARACTERIZATION OF BACTEREMIC AND NON-BACTEREMIC SYNDROMES OF INVASIVE ESCHERICHIA COLI DISEASE AMONG HOSPITALIZED ADULTS AGED ≥60 YEARS: FINDINGS FROM A PROSPECTIVE, MULTINATIONAL, OBSERVATIONAL STUDY (EXPECT-2) |
| has_fulltext | True |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T13569 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9927999973297119 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2713 |
| primary_topic.subfield.display_name | Epidemiology |
| primary_topic.display_name | Microscopic Colitis |
| related_works | https://openalex.org/W4301072685, https://openalex.org/W2051018641, https://openalex.org/W2411369229, https://openalex.org/W3167838867, https://openalex.org/W1963891627, https://openalex.org/W4311263383, https://openalex.org/W2138999771, https://openalex.org/W2411307492, https://openalex.org/W2122351330, https://openalex.org/W2083518073 |
| cited_by_count | 0 |
| locations_count | 2 |
| best_oa_location.id | doi:10.1016/j.ijid.2023.04.271 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S35071406 |
| best_oa_location.source.issn | 1201-9712, 1878-3511 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 1201-9712 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | International Journal of Infectious Diseases |
| best_oa_location.source.host_organization | https://openalex.org/P4310320990 |
| best_oa_location.source.host_organization_name | Elsevier BV |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320990 |
| best_oa_location.source.host_organization_lineage_names | Elsevier BV |
| best_oa_location.license | |
| best_oa_location.pdf_url | https://doi.org/10.1016/j.ijid.2023.04.271 |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | International Journal of Infectious Diseases |
| best_oa_location.landing_page_url | https://doi.org/10.1016/j.ijid.2023.04.271 |
| primary_location.id | doi:10.1016/j.ijid.2023.04.271 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S35071406 |
| primary_location.source.issn | 1201-9712, 1878-3511 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 1201-9712 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | International Journal of Infectious Diseases |
| primary_location.source.host_organization | https://openalex.org/P4310320990 |
| primary_location.source.host_organization_name | Elsevier BV |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320990 |
| primary_location.source.host_organization_lineage_names | Elsevier BV |
| primary_location.license | |
| primary_location.pdf_url | https://doi.org/10.1016/j.ijid.2023.04.271 |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | International Journal of Infectious Diseases |
| primary_location.landing_page_url | https://doi.org/10.1016/j.ijid.2023.04.271 |
| publication_date | 2023-05-01 |
| publication_year | 2023 |
| referenced_works_count | 0 |
| abstract_inverted_index.6 | 242 |
| abstract_inverted_index.a | 43, 66, 75 |
| abstract_inverted_index.11 | 238 |
| abstract_inverted_index.28 | 113 |
| abstract_inverted_index.47 | 141 |
| abstract_inverted_index.E. | 36, 68, 249, 283 |
| abstract_inverted_index.Of | 237, 247 |
| abstract_inverted_index.as | 121, 276 |
| abstract_inverted_index.by | 65, 294 |
| abstract_inverted_index.in | 5, 25, 83, 127, 180, 226 |
| abstract_inverted_index.is | 3 |
| abstract_inverted_index.of | 12, 34, 86, 89, 157, 174, 195, 282 |
| abstract_inverted_index.or | 79, 100 |
| abstract_inverted_index.to | 27, 124 |
| abstract_inverted_index.193 | 137 |
| abstract_inverted_index.238 | 258 |
| abstract_inverted_index.294 | 248 |
| abstract_inverted_index.IED | 24, 51, 62, 116, 170, 191, 234, 274, 291 |
| abstract_inverted_index.MDR | 118, 260, 299 |
| abstract_inverted_index.The | 132, 155, 172, 193, 215 |
| abstract_inverted_index.and | 9, 22, 30, 59, 106, 140, 152, 168, 189, 197, 202, 207, 209, 232, 267, 289, 298 |
| abstract_inverted_index.for | 205, 212, 265, 270 |
| abstract_inverted_index.had | 244 |
| abstract_inverted_index.set | 135 |
| abstract_inverted_index.the | 84, 177, 222 |
| abstract_inverted_index.was | 42, 63, 119, 221 |
| abstract_inverted_index.who | 240 |
| abstract_inverted_index.2019 | 58 |
| abstract_inverted_index.IED) | 82 |
| abstract_inverted_index.IED. | 154, 214, 246 |
| abstract_inverted_index.MDR. | 287 |
| abstract_inverted_index.SIRS | 161 |
| abstract_inverted_index.SOFA | 102, 182 |
| abstract_inverted_index.This | 18 |
| abstract_inverted_index.aged | 53 |
| abstract_inverted_index.body | 77 |
| abstract_inverted_index.both | 225 |
| abstract_inverted_index.coli | 15, 37, 69, 250, 284 |
| abstract_inverted_index.data | 2 |
| abstract_inverted_index.days | 114 |
| abstract_inverted_index.from | 71, 257 |
| abstract_inverted_index.full | 133 |
| abstract_inverted_index.most | 216 |
| abstract_inverted_index.non- | 142 |
| abstract_inverted_index.room | 224 |
| abstract_inverted_index.site | 78 |
| abstract_inverted_index.that | 48 |
| abstract_inverted_index.were | 110, 148, 163, 184, 200, 262, 292 |
| abstract_inverted_index.with | 159, 176, 228, 252, 279 |
| abstract_inverted_index.≥1 | 125 |
| abstract_inverted_index.≥2 | 160 |
| abstract_inverted_index.≥3 | 128 |
| abstract_inverted_index.(MDR) | 33 |
| abstract_inverted_index.2021. | 61 |
| abstract_inverted_index.34.7% | 263 |
| abstract_inverted_index.37.2% | 268 |
| abstract_inverted_index.7.1%, | 210 |
| abstract_inverted_index.75.0% | 201 |
| abstract_inverted_index.83.3% | 208 |
| abstract_inverted_index.IED), | 74 |
| abstract_inverted_index.Organ | 96 |
| abstract_inverted_index.blood | 72 |
| abstract_inverted_index.died, | 241 |
| abstract_inverted_index.quick | 101 |
| abstract_inverted_index.rates | 156, 173, 194, 261 |
| abstract_inverted_index.score | 183 |
| abstract_inverted_index.shock | 199 |
| abstract_inverted_index.study | 19, 47 |
| abstract_inverted_index.total | 181 |
| abstract_inverted_index.urine | 80 |
| abstract_inverted_index.years | 55 |
| abstract_inverted_index.≥60 | 54 |
| abstract_inverted_index.(IED). | 17 |
| abstract_inverted_index.11.4%, | 203 |
| abstract_inverted_index.Intro: | 0 |
| abstract_inverted_index.burden | 11 |
| abstract_inverted_index.change | 179 |
| abstract_inverted_index.common | 217 |
| abstract_inverted_index.sepsis | 196 |
| abstract_inverted_index.septic | 198 |
| abstract_inverted_index.severe | 277 |
| abstract_inverted_index.(16/43) | 269 |
| abstract_inverted_index.(19.6%) | 144 |
| abstract_inverted_index.(31.5%, | 230 |
| abstract_inverted_index.(35.9%, | 235 |
| abstract_inverted_index.(54.5%) | 243 |
| abstract_inverted_index.(62.2%) | 188 |
| abstract_inverted_index.(64.8%) | 167 |
| abstract_inverted_index.(80.4%) | 139 |
| abstract_inverted_index.(SIRS), | 94 |
| abstract_inverted_index.(SOFA), | 99 |
| abstract_inverted_index.Failure | 97 |
| abstract_inverted_index.January | 60 |
| abstract_inverted_index.October | 57 |
| abstract_inverted_index.Patient | 146 |
| abstract_inverted_index.between | 56, 150, 165, 186 |
| abstract_inverted_index.culture | 70 |
| abstract_inverted_index.defined | 64, 120 |
| abstract_inverted_index.disease | 10, 16 |
| abstract_inverted_index.limited | 4 |
| abstract_inverted_index.medical | 108, 219 |
| abstract_inverted_index.similar | 295 |
| abstract_inverted_index.sterile | 76 |
| abstract_inverted_index.testing | 255 |
| abstract_inverted_index.through | 112 |
| abstract_inverted_index.(53.2%). | 192 |
| abstract_inverted_index.(70.2%). | 171 |
| abstract_inverted_index.(87/251) | 264 |
| abstract_inverted_index.(qSOFA). | 103 |
| abstract_inverted_index.EXPECT-2 | 40 |
| abstract_inverted_index.Methods: | 39 |
| abstract_inverted_index.Response | 92 |
| abstract_inverted_index.Syndrome | 93 |
| abstract_inverted_index.Systemic | 90 |
| abstract_inverted_index.acquired | 122 |
| abstract_inverted_index.analysis | 134 |
| abstract_inverted_index.assessed | 111 |
| abstract_inverted_index.balanced | 149 |
| abstract_inverted_index.classes. | 130 |
| abstract_inverted_index.clinical | 7, 28, 296 |
| abstract_inverted_index.criteria | 88, 162 |
| abstract_inverted_index.enrolled | 50 |
| abstract_inverted_index.features | 8, 29, 297 |
| abstract_inverted_index.included | 136 |
| abstract_inverted_index.invasive | 13 |
| abstract_inverted_index.isolates | 251, 285 |
| abstract_inverted_index.patients | 52, 158, 175, 227, 239 |
| abstract_inverted_index.positive | 67 |
| abstract_inverted_index.presence | 85 |
| abstract_inverted_index.relation | 26 |
| abstract_inverted_index.Findings: | 131 |
| abstract_inverted_index.Published | 1 |
| abstract_inverted_index.[14/39]). | 236 |
| abstract_inverted_index.[41/130]) | 231 |
| abstract_inverted_index.causative | 35 |
| abstract_inverted_index.collected | 256 |
| abstract_inverted_index.emergency | 223 |
| abstract_inverted_index.encounter | 220 |
| abstract_inverted_index.following | 115 |
| abstract_inverted_index.isolates. | 38, 272 |
| abstract_inverted_index.mortality | 105 |
| abstract_inverted_index.multidrug | 31 |
| abstract_inverted_index.one-third | 281 |
| abstract_inverted_index.patients, | 259 |
| abstract_inverted_index.patients. | 145 |
| abstract_inverted_index.requisite | 87 |
| abstract_inverted_index.Assessment | 98 |
| abstract_inverted_index.Bacteremic | 288 |
| abstract_inverted_index.Sequential | 95 |
| abstract_inverted_index.antibiotic | 126 |
| abstract_inverted_index.bacteremic | 21, 138, 143, 151, 166, 187, 229, 245, 266 |
| abstract_inverted_index.comparable | 164, 185 |
| abstract_inverted_index.describing | 6 |
| abstract_inverted_index.diagnosis. | 117 |
| abstract_inverted_index.displaying | 286 |
| abstract_inverted_index.encounters | 109 |
| abstract_inverted_index.infection, | 278 |
| abstract_inverted_index.manifested | 275 |
| abstract_inverted_index.resistance | 32 |
| abstract_inverted_index.≥2-point | 178 |
| abstract_inverted_index.(bacteremic | 73 |
| abstract_inverted_index.Conclusion: | 273 |
| abstract_inverted_index.Escherichia | 14 |
| abstract_inverted_index.IED-related | 107, 218 |
| abstract_inverted_index.In-hospital | 104 |
| abstract_inverted_index.bacteremic, | 206 |
| abstract_inverted_index.phenotypes. | 300 |
| abstract_inverted_index.Inflammatory | 91 |
| abstract_inverted_index.demographics | 147 |
| abstract_inverted_index.(NCT04117113) | 41 |
| abstract_inverted_index.antimicrobial | 129, 253 |
| abstract_inverted_index.approximately | 280 |
| abstract_inverted_index.characterized | 20, 293 |
| abstract_inverted_index.observational | 46 |
| abstract_inverted_index.prospectively | 49 |
| abstract_inverted_index.respectively, | 204, 211 |
| abstract_inverted_index.multinational, | 44 |
| abstract_inverted_index.non-bacteremic | 23, 153, 169, 190, 213, 233, 271, 290 |
| abstract_inverted_index.susceptibility | 254 |
| abstract_inverted_index.(non-bacteremic | 81 |
| abstract_inverted_index.hospital-based, | 45 |
| abstract_inverted_index.non-susceptibility | 123 |
| cited_by_percentile_year | |
| countries_distinct_count | 11 |
| institutions_distinct_count | 19 |
| citation_normalized_percentile.value | 0.13182549 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |